Alliance A022102: Randomized phase III trial of mFOLFIRINOX plus /- nivolumab vs. FOLFOX plus /- nivolumab for first-line treatment of metastatic HER2-negative gastroesophageal adenocarcinoma (GEA)

被引：0

作者：

Park, Haeseong

Geyer, Susan Michelle

Klute, Kelsey

Bleeker, Jonathan

King, Daniel

Strickland, Matthew

Goodrich, Austin

Carlisle, Destin

Shergill, Ardaman

O'Reilly, Eileen Mary

Meyerhardt, Jeffrey A.

Shah, Manish A.

机构：

[1] Dana Farber Canc Inst, Boston, MA USA

[2] Mayo Clin, Alliance Stat & Data Management Ctr, Rochester, MN USA

[3] Mayo Clin, Rochester, MN USA

[4] Univ Nebraska Med Ctr, Omaha, NE USA

[5] Sanford Hlth, Sioux Falls, SD USA

[6] Northwell Hlth, New Hyde Pk, NY USA

[7] Massachusetts Gen Hosp, Boston, MA USA

[8] Univ Chicago, Alliance Protocol Operat Off, Chicago, IL USA

[9] Mem Sloan Kettering Canc Ctr, New York, NY USA

[10] Weill Cornell Med, New York Presbyterian Hosp, New York, NY USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期

基金：

美国国家卫生研究院;

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

TPS4175

引用

页数：1

共 50 条

[31] SAKK 24/09: safety and tolerability of bevacizumab plus paclitaxel vs. bevacizumab plus metronomic cyclophosphamide and capecitabine as first-line therapy in patients with HER2-negative advanced stage breast cancer - a multicenter, randomized phase III trial
Rochlitz, Christoph
Bigler, Martin
von Moos, Roger
Bernhard, Jurg
Matter-Walstra, Klazien
Wicki, Andreas
Zaman, Khalil
Anchisi, Sandro
Kung, Marc
Na, Kyung-Jae
Bartschi, Daniela
Borner, Markus
Rordorf, Tamara
Rauch, Daniel
Mueller, Andreas
Ruhstaller, Thomas
Vetter, Marcus
Trojans, Andreas
Hasler-Strub, Ursula
Cathomas, Richard
Winterhalder, Ralph
BMC CANCER, 2016, 16
[32] SAKK 24/09: safety and tolerability of bevacizumab plus paclitaxel vs. bevacizumab plus metronomic cyclophosphamide and capecitabine as first-line therapy in patients with HER2-negative advanced stage breast cancer - a multicenter, randomized phase III trial
Christoph Rochlitz
Martin Bigler
Roger von Moos
Jürg Bernhard
Klazien Matter-Walstra
Andreas Wicki
Khalil Zaman
Sandro Anchisi
Marc Küng
Kyung-Jae Na
Daniela Bärtschi
Markus Borner
Tamara Rordorf
Daniel Rauch
Andreas Müller
Thomas Ruhstaller
Marcus Vetter
Andreas Trojan
Ursula Hasler-Strub
Richard Cathomas
Ralph Winterhalder
BMC Cancer, 16
[33] Health economic evaluation of: Bevacizumab plus paclitaxel vs. bevacizumab plus metronomic cyclophosphamide and capecitabine as first-line therapy in patients with HER2-negative advanced breast cancer: A multicenter, randomized phase III trial - SAKK 24/0
Matter-Walstra, Klazien W.
Bigler, Martin
Schwenkglenks, Matthias
Bertschi, Daniela
Brechbuehl, Joerg
Hasler-Strub, Ursula
von Moos, Roger
Mueller, Andreas
Winterhalder, Ralph
Rochlitz, Christoph
CANCER RESEARCH, 2015, 75
[34] FOLFOX plus ziv-aflibercept or placebo in first-line metastatic esophagogastric adenocarcinoma: A double-blind, randomized, multicenter phase 2 trial
Cleary, James M.
Horick, Nora K.
McCleary, Nadine Jackson
Abrams, Thomas A.
Yurgelun, Matthew B.
Azzoli, Christopher G.
Rubinson, Douglas A.
Brooks, Gabriel A.
Chan, Jennifer A.
Blaszkowsky, Lawrence S.
Clark, Jeffrey W.
Goyal, Lipika
Meyerhardt, Jeffrey A.
Ng, Kimmie
Schrag, Deborah
Savarese, Diane M. F.
Graham, Christopher
Fitzpatrick, Bridget
Gibb, Kathryn A.
Boucher, Yves
Duda, Dan G.
Jain, Rakesh K.
Fuchs, Charles S.
Enzinger, Peter C.
CANCER, 2019, 125 (13) : 2213 - 2221
[35] Phase II, multicentre, randomised trial of eribulin plus gemcitabine versus paclitaxel plus gemcitabine as first-line chemotherapy in patients with HER2-negative metastatic breast cancer
Park, Yeon Hee
Im, Seock-Ah
Kim, Sung-Bae
Sohn, Joo Hyuk
Lee, Keun Seok
Chae, Yee Soo
Lee, Ki Hyeong
Kim, Jee Hyun
Im, Young-Hyuck
Kim, Ji-Yeon
Kim, Tae-Yong
Lee, Kyung-Hun
Ahn, Jin-Hee
Kim, Gun Min
Park, In Hae
Lee, Soo Jung
Han, Hye Sook
Kim, Se Hyun
Jung, Kyung Hae
EUROPEAN JOURNAL OF CANCER, 2017, 86 : 385 - 393
[36] Nivolumab plus chemotherapy in first-line metastatic non-small-cell lung cancer: results of the phase III CheckMate 227 Part 2 trial
Borghaeit, H.
O'Byrnet, K. J.
Paz-Ares, L.
Ciuleanu, T. -E
Yu, X.
Pluzanski, A.
Nagrial, A.
Havel, L.
Kowalyszyn, R. D.
Valette, C. A.
Brahmer, J. R.
Reck, M.
Ramalingam, S. S.
Zhang, L.
Ntambwe, I.
Rabindran, S. K.
Nathan, F. E.
Balli, D.
Wu, Y. -L.
ESMO OPEN, 2023, 8 (06)
[37] Nivolumab plus ipilimumab vs chemotherapy as first-line treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma: CheckMate 649 biomarker analyses
Janjigian, Yelena Y.
Shitara, Kohei
Ajani, Jaffer
Moehler, Markus
Yao, Jin
Shen, Lin
Garrido, Marcelo
Gallardo, Carlos
Wyrwicz, Lucjan
Yamaguchi, Kensei
Skoczylas, Tomasz
Bragagnoli, Arinilda
Liu, Tianshu
Schenker, Michael
Yanez, Patricio
Kowalyszyn, Ruben
Karamouzis, Michalis
Zander, Thomas
Feeney, Kynan
Elimova, Elena
Nathani, Raheel
Novosiadly, Ruslan
Lei, Ming
CANCER RESEARCH, 2023, 83 (08)
[38] An Indirect Comparison Between Nivolumab plus Ipilimumab plus Two Cycles of Chemotherapy vs. Pembrolizumab plus Chemotherapy as First-Line Treatment for Metastatic Non-Small Cell Lung Cancer
Jiang, Panpan
Mao, Ziyang
Wang, Qinyang
Jia, Xiaohui
Geng, Luying
Xu, Hong
Jiang, Lili
Yang, Chengcheng
Jiao, Min
Guo, Hui
FRONTIERS IN ONCOLOGY, 2021, 11
[39] MATCHING-ADJUSTED INDIRECT TREATMENT COMPARISON OF TREMELIMUMAB plus DURVALUMAB plus CHEMOTHERAPY VS PEMBROLIZUMAB plus CHEMOTHERAPY AND NIVOLUMAB plus IPILIMUMAB plus CHEMOTHERAPY FOR FIRST-LINE METASTATIC NSCLC
Johal, Sukhvinder
Miranda, Miguel
Sarbajna, Tina
Shi, Xiaojin
Greystoke, Alastair
Johnson, Melissa
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 : A608 - A608
[40] The efficacy of bevacizumab plus paclitaxel as first-line treatment for HER2-negative metastatic breast cancer: a meta-analysis of randomized controlled trials
Wang, Xuan
Huang, Chun
Li, Man
Gu, Yanjun
Cui, Yanfen
Li, Yan
TUMOR BIOLOGY, 2014, 35 (05) : 4841 - 4848

← 1 2 3 4 5 →